134 related articles for article (PubMed ID: 15806124)
1. Successful non-T-cell-depleted HLA-haploidentical stem cell transplantation (SCT) with reduced-intensity conditioning from a second child for late graft failure after the first HLA-haploidentical SCT for MDS/overt leukemia based on feto-maternal microchimerism.
Fuchida S; Nakano S; Yamada N; Uchida R; Okano A; Okamoto M; Maruya E; Saji H; Shimazaki C
Bone Marrow Transplant; 2005 May; 35(10):1031-2. PubMed ID: 15806124
[No Abstract] [Full Text] [Related]
2. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance.
Obama K; Utsunomiya A; Takatsuka Y; Takemoto Y
Bone Marrow Transplant; 2004 Nov; 34(10):897-9. PubMed ID: 15361902
[TBL] [Abstract][Full Text] [Related]
3. Successful reduced-intensity HLA-haploidentical stem cell transplantation based on the concept of feto-maternal tolerance for an elderly patient with myelodysplastic syndrome.
Obama K; Takemoto Y; Takatsuka Y; Utsunomiya A
Bone Marrow Transplant; 2004 Jan; 33(2):253. PubMed ID: 14647244
[No Abstract] [Full Text] [Related]
4. Non-T-cell-depleted HLA-haploidentical stem cell transplantation after reduced-intensity conditioning in advanced haematological malignancies based on feto-maternal microchimerism.
Shimazaki C; Fuchida S; Ochiai N; Nakano S; Yamada N; Uchida R; Okamoto M; Okano A; Inaba T; Maruya E; Saji H
Br J Haematol; 2004 Nov; 127(4):474-5. PubMed ID: 15521926
[No Abstract] [Full Text] [Related]
5. Non-T-cell-depleted HLA haploidentical stem cell transplantation based on feto-maternal microchimerism in pediatric patients with advanced malignancies.
Yoshihara T; Morimoto A; Inukai T; Kuroda H; Ishida H; Sugita K; Goi K; Imamura T; Todo S; Maruya E; Saji H; Nakazawa S; Imashuku S
Bone Marrow Transplant; 2004 Aug; 34(4):373-5. PubMed ID: 15220959
[No Abstract] [Full Text] [Related]
6. Successful non-T cell-depleted HLA haplo-identical three-loci mismatched hematopoietic stem cell transplantation from mother to son based on the feto-maternal microchimerism in chronic myelogenous leukemia.
Ochiai N; Shimazaki C; Fuchida S; Okano A; Sumikuma T; Ashihara E; Inaba T; Fujita N; Maruya E; Nakagawa M
Bone Marrow Transplant; 2002 Dec; 30(11):793-6. PubMed ID: 12439703
[TBL] [Abstract][Full Text] [Related]
7. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
8. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.
Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582
[TBL] [Abstract][Full Text] [Related]
9. The haploidentical option for high-risk haematological malignancies.
Aversa F; Reisner Y; Martelli MF
Blood Cells Mol Dis; 2008; 40(1):8-12. PubMed ID: 17905610
[TBL] [Abstract][Full Text] [Related]
10. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
Koh LP; Rizzieri DA; Chao NJ
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1249-67. PubMed ID: 17950913
[TBL] [Abstract][Full Text] [Related]
15. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
16. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
17. Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantation.
Yagyu S; Kuroda H; Fujiki A; Tamura S; Iehara T; Morimoto A; Hosoi H; Sugimoto T; Imashuku S
Eur J Haematol; 2005 Jun; 74(6):529-32. PubMed ID: 15876259
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for myelodysplastic syndrome.
Barrett AJ; Savani BN
Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation for myelodysplastic syndrome (MDS).
Ingram W; Lim ZY; Mufti GJ
Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
[TBL] [Abstract][Full Text] [Related]
20. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
